Bris­tol-My­ers vet Dou­glas Man­ion bids Big Phar­ma farewell, takes the helm at Yale spin­out Kleo

A 12-year vet­er­an of Bris­tol-My­ers Squibb’s R&D group is join­ing the mi­gra­tion of re­search ex­ecs out of Big Phar­ma and in­to up-and-com­ing biotech.

Dou­glas Man­ion is hang­ing up his spurs as head of spe­cial­ty de­vel­op­ment for BMS and tak­ing over as CEO of an up­start named Kleo Phar­ma­ceu­ti­cals, which is pur­su­ing new drugs spot­light­ed in the lab of Yale’s David Spiegel. Kleo’s fo­cus is on small mol­e­cules that can do the job a wave of bi­o­log­ics have been do­ing in spurring an im­mune sys­tem at­tack.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.